Breaking News

Pfizer Acquires NextWave

November 28, 2012

Gains rights to liquid ADHD treatment

Pfizer has acquired NextWave Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).
 
Pfizer now has exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, the first once-daily liquid medication approved in the U.S. to treat ADHD. Quillivant XR was approved by the FDA in September and is expected to be available in January 2013. Financial terms of the acquisitions were not disclosed
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks